T[he]{.smallcaps}actin cytoskeleton plays crucial roles in fundamental processes such as cell growth, differentiation and migration, localized membrane growth, endocytosis, and cell division. *Saccharomyces cerevisiae* is an excellent organism for the study of the actin cytoskeleton because many of its components are conserved ([@B16]) and it is possible to probe the function of particular components in yeast via genetic approaches. *S. cerevisiae* cells display cytoskeletal asymmetry during the cell cycle. As cells initiate a cell cycle, the cytoskeleton becomes organized anisotropically to facilitate polarized growth. In G1, a ring of actin marks the site where the bud will grow. In S and G2, as the bud continues its growth, the actin cytoskeleton remains highly polarized toward the bud. Cortical patches are concentrated mainly in the bud and cables are visible converging toward the mother--bud axis. After cell division, the newly formed cells are unpolarized and another round of polarization starts with a new cell cycle ([@B1]). During the cell cycle the actin cytoskeleton plays roles in bipolar bud-site selection and polarized secretion of components, as well as polarized movement of organelles such as mitochondria to the daughter cell ([@B40]; [@B48]; [@B51]).

The actin cytoskeleton is also important for processes not necessarily associated with the cell cycle, such as endocytosis ([@B32]). In our efforts to identify cellular components involved in the distribution of nucleus-encoded proteins to mitochondria, we identified mutations of *VRP1*, *PAN1*, ([@B53]) and *RSP5* ([@B54]). Interestingly, all of these genes affect endocytosis and show genetic interactions with each other and/or with components of the actin cytoskeleton ([@B32]; [@B53]; [@B49]; [@B54]). The current studies focus on deciphering the cellular function of the *VRP1* gene product.

*VRP1* codes for verprolin, a 817--amino acid protein very rich (22%) in proline. Besides a defect in the ability to grow at elevated temperatures, *vrp1* mutants have aberrant cytoskeletons ([@B13]; [@B53]), defects in cytoplasmic/mitochondrial distribution of a mitochondrial protein ([@B53]), and defects in endocytosis ([@B32]; [@B54]). We provide evidence here that verprolin is also required for bipolar budding patterns. How verprolin is involved in these diverse processes is not understood. In particular, it is not known whether all the defects are related to the cytoskeletal disorganization or whether verprolin has multiple functions in yeast.

In attempts to clone *VRP1*, *ACT1* encoding actin was uncovered as a suppressor of the *vrp1-1* mutation. We showed that when supplied with actin encoded from a low copy centromere-containing vector or from a single additional integrated copy of *ACT1*, *vrp1-1* mutant cells could grow at the nonpermissive temperature; however, *ACT1* did not suppress the temperature-sensitive (ts)^1^ growth defect caused by a disruption allele of *VRP1*, *vrp1::LEU2* ([@B53]). Therefore, an apparent increase in the intracellular concentration of actin caused allele-specific suppression of the ts growth defects of *vrp1* mutant cells. To begin to understand the role of verprolin in yeast, we determined which of the defects of *vrp1* mutant cells could be corrected by *ACT1.* Here we show that actin supplied from a low copy centromere-containing vector corrects all *vrp1* defects.

We show that verprolin is an actin-binding protein located at positions coincident with the actin cortical cytoskeleton. Many other actin-binding proteins are localized similarly to verprolin (Doyle et al., 1996; [@B4]; Waddle et al., 1997). The cytoskeletal location of many actin-binding proteins is dependent upon an appropriate cytoskeleton. However, the polarized locations of some actin-binding proteins can be actin cytoskeleton independent ([@B5]). Our results demonstrate that verprolin achieves its intracellular localization through an actin-independent pathway. The pattern of intracellular localization of verprolin, its independence from actin, its role in bud-site selection, as well as the phenotypes of *vrp1* mutants provide evidence that verprolin is a polarity development protein required for the correct assembly of the actin cytoskeleton.

Materials and Methods
=====================

Strains and Genetic Techniques
------------------------------

Media for yeast growth were prepared according to [@B38]. Cells were transformed by the one-step method described by [@B11]. The strains used in this study are listed in Table [I](#TI){ref-type="table"}.

General DNA Manipulations
-------------------------

DNA manipulations were done using standard techniques ([@B37]). *Escherichia coli* strains employed were DH5α and RR1. Restriction endonucleases and modifying enzymes were obtained from New England Biolabs Inc. (Beverly, MA) or from Promega (Madison, WI). Sequenase was obtained from United States Biochemical Corp., (Cleveland, Ohio).

Plasmid Construction
--------------------

To construct the *VRP1--green fluorescent protein (GFP)* fusion, a 0.7-kb PCR product containing the *GFP* open reading frame (ORF) from pSEY18/GAL1-10/GFP (gift from Roger Y. Tsien, University of California, San Diego, CA) was obtained using the following primers: the 5′oligo, 5′GCCCCGGGCATGAGTAAAGGAGAAGAACTTTTC3′ and the 3′oligo, 5′CATTCCCGGGTATAGTTCATCCATGCCATG3′. The PCR fragment contained built-in SmaI ends and the amplified DNA was cloned into pGEM-T vectors. From pGEM-T vectors the 0.7-kb *GFP* was released by digesting with SmaI and further cloned in-frame at the carboxy terminus of *VRP1* that had been digested at the unique BsaAI site, one codon before the stop codon. The ∼4.7-kb HindIII piece containing the *VRP1--GFP* fusion and the *VRP1* regulatory sequences were transferred to the single-copy yeast shuttle vector YCplac33 generating YCpVRP1GFP.

For YCpVRP1 plasmid, a 4-kb piece containing the *VRP1* gene was removed from the pT6 plasmid ([@B53]) by digesting with HindIII and cloned into pUC19. From pUC19, the 4-kb Hind III fragment containing *VRP1* was further cloned into YCplac33 vector giving rise to YCpVRP1.

For all two-hybrid constructs, two vectors were used: pACT2, encoding the Gal4 DNA transcription activation domain, and pAS-CYH2, encoding the Gal4 DNA-binding domain. Both vectors were a gift from S.J. Elledge (Baylor College of Medicine, Houston, TX). To eliminate possible confusion related to the nomenclature of vector and genes we cloned in these vectors, we designated pACT2 as pDAD, for *D*NA *A*ctivating *D*omain. In the same way, pAS-CYH2 was replaced by pDBD for *D*NA- *B*inding *D*omain in the name of all constructs.

For pDAD-VRP1 or pDBD-VRP1, a 2.5-kb PCR product containing the *VRP1* ORF and 71 bp from the trimer of the hemagglutinin (HA) epitope was cloned into pGEM-T giving rise to pGEM-VRP1-2Hy. The 5′oligo was 5′GTACGGATCCAAATGGCAGGTGCTCCA3′ and the 3′ oligo was 5′TCATATGGATAGGATCC3′. Both oligos have built-in BamHI ends. The ∼2.6-kb BamHI fragment was transferred to pDAD or pDBD vectors to generate in-frame fusions between Gal4p DNA-binding domain or the Gal4p transcription activation domain and Vrp1p.

pDAD-ACT1 and pDBD-ACT1 were constructed in the following way: a 1.1-kb PCR product containing the *ACT1* ORF following the intron was cloned into pGEM-T vector giving rise to pGEM-ACTIN. For the PCR reaction, the template was pT3 ([@B53]). Use of the 5′ oligo, 5′GTACGGATCCAGGTTGCTGCTTTGGTT3′, eliminates the codons before the intron in the *ACT1* gene. The 3′ oligo was 5′CAGTGGATCCACACAAAAGCAGAGATTA3′. Both oligos have built-in BamHI ends. From pGEM-ACTIN the BamHI fragment containing the *ACT1* coding region was transferred to pDAD or pDBD.

For pDAD-PFY or pDBD-PFY the following procedure was used: a 0.35-kb PCR product containing the *PFY1* ORF following the intron was cloned into pGEM-T giving rise to pGEM-PFY. For the PCR reaction the template was YCpPFY1 (a gift from S.S. Brown, University of Michigan, Ann Arbor, MI), the 5′ oligo was 5′GTACGGATCCCATACACTGATAACTTA3′ and the 3′ oligo was 5′GTACGGATCCAAATTAGTATTGAACACC3′. Both oligos have built-in BamHI ends. The BamHI fragment was transferred to pDAD or pDBD.

For constructing pDAD-VRP1ΔSalΔKpn1-2, the pGEM-VRP1-2Hy plasmid was digested with SalI and the 4.1-kb piece containing the plasmid backbone and amino terminus of *VRP1* coding for 363 amino acids was ligated and further digested with KpnI. The release of an internal 0.35-kb KpnI fragment and further ligation at this KpnI site generated an out-of-frame fusion beyond codon 70, and generated pGEM-VRP1Δ SalΔKpn1-2. This construct encodes *VRP1* amino acids 1--70. The ∼0.9-kb BamHI--SalI fragment was then cloned into pDAD digested BamHI--SalI giving rise to pDAD-VRP1ΔSalΔKpn1-2.

For pDAD-VRP1ΔKpn1-3, the pGEM-VRP1-2Hy plasmid was digested with KpnI and two pieces, 0.3 and 0.7 kb were released. The backbone plasmid was then closed to create an in-frame fusion between amino acids 70 and 717 of Vrp1p. This plasmid, pGEM-VRP1ΔKpn1-3, encodes the amino terminus (amino acids 1--70) and the carboxy end (amino acids 717--817) of verprolin fused in frame to the Gal4p DNA transcription activation domain. The ∼0.5-kb BamHI fragment was removed and cloned in frame into pDAD.

For pDAD-VRP1 71-817, a ∼2.2-kb PCR product of *VRP1* coding for a protein missing the first 70 amino acids was first cloned into pGEM-T vectors. From pGEM-T, the 2.2-kb *VRP1* fragment containing built-in BamHI ends was cut out and cloned into the pDAD vector. For PCR, the 5′ oligo was: 5′GGGATCCGTACCGTCAGTAGTAAAGGACCC3′ and the 3′ oligo was 5′TCATATGGATAGGATCC3′.

pDAD-VRP1ΔSalΔKpn1-2/EE contains a fusion between the Gal4-DNA--activating domain and the first 70 amino acids of verprolin in which the two lysines in the LKKAET motif have been mutated to glutamic acids. To construct this plasmid, pGEM-VRP1ΔSalΔKpn1-2 was used for reverse PCR ([@B24]). 5′GAGGAGGCTGAGACCAATGATAGAAGTGCCCCAATC3′ and 5′TAGTTTCATTCCCTTTCTA- ATGTCACC3′ were the primers used. The correct sequences of the 70-- amino acids coding region was verified by DNA sequencing. After removing the A-tails of the PCR product with T4 polymerase and phosphorylation with T4 kinase, the PCR product was circularized with T4 ligase. The BamHI--SalI piece was removed and cloned in pDAD vector-digested BamHI--SalI to give rise to pDAD-VRP1ΔSalΔKpn1-2/EE.

YCpVRP1-HA was constructed as follows: a 4-kb HindIII *VRP1* piece including the promoter region and the 3′UTR was cloned into pUC19, giving rise to pUCH. This plasmid was digested at the unique BsaAI site, one codon before the stop codon in *VRP1* gene, and a HaeIII fragment containing roughly three copies of the hemmaglutinin trimer was placed in frame at the BsaAI site, creating the tagged version of *VRP1.* From pUC19 the HindIII piece containing the tagged *VRP1* was digested and cloned in YCplac33 vector giving rise to YCpVRP1-HA.

pT3 is a plasmid from a library inserted into a centromere-containing vector that contains the *ACT1* gene. Transposon mutagenesis of the genomic insert of this plasmid showed that *ACT1* is responsible for complementation of the *vrp1-1* mutation ([@B53]).

YCpLEUMod5p-I,KR6ET, a low copy plasmid bearing a hemagglutinin trimer-tagged version of Mod5p-I,KR6, was a gift from T. Zoladek (Polish Academy of Sciences, Warsaw, Poland).

Two-hybrid Analysis
-------------------

Two-hybrid studies were done according to [@B12]. The host strain for two-hybrid studies was Y190, a derivative of Y153, and kindly provided by S.J. Elledge ([@B18]). Strain Y190 was transformed sequentially with each of the pairs of plasmids tested. Nitrocellulose membrane lifts, assays of β-galactosidase activity, and growth on leu^−^trp^−^his^−^ plates were done according to recommendations ([@B18]). Growth on media-lacking histidine was tested in the presence of 25, 50, and 100 mM 3--amino-1,2,4-triazole.

Microscopic Imaging and Analysis
--------------------------------

For verprolin-GFP localization studies, cells from exponentially growing cultures or from a one-day fresh plate were used. Cells were spotted on microscope slide, covered with a coverslip and visualized immediately under a 60× objective (1.4 numerical aperture) using either FITC-filtered illumination or differential interference contrast (DIC) optics. Pictures were taken on Kodak T-Max 400. A Nikon Microphot-FX equipped with B-1E filter cube/420--490 excitation filter/5151F barrier filter was used.

For verprolin-HA and actin staining in the same cells, indirect immunofluorescence was done as follows: 10 ml logarithmic cultures were fixed with 5% formaldehyde for 30 min, washed twice with 1× PBS, pH 6.5, treated with 0.2% Triton X-100 for 10 min, digested 45 min with zymolyase 20T in the presence of β-mercaptoethanol, washed once with sol. B (1.2 M sorbitol, 40 mM phosphate buffer, pH 6.5, 0.05 mM MgCl~2~). After incubating for an additional 10 min with 0.2% Triton X-100, cells were incubated with primary antibody against HA (12CA5; BAbCO, Richmond, CA) at a 1:750 dilution for 1 h in solution, washed once with PBS, and then incubated with secondary Cy3-conjugated goat anti--mouse antibody (Jackson Immunoresearch Laboratories, Inc., West Grove, PA) at a 1:600 dilution for 45 min. Cells were then washed two times with PBS, and stained with 3.3 μM Oregon green 488 phalloidin in the dark for 30 min. Cells were washed once and mounted on slides. Images were acquired and digitized directly with a SenSys (Photometrics Ltd., Tucson, AZ) CCD camera coupled to a Nikon Optiphot-2 microscope. Illumination was controlled by a Lambda 10-2C filter-wheel controller (Sutter Instrument Company, Novato, CA). Image processing was done using IPLab Spectrum software (Signal Analytics, Co., Vienna, VA) running on a 6500/225 Power Macintosh. Files were converted into and further processed using Adobe Photoshop 4.

Staining
--------

For all experiments, except for the co-localization studies described above, rhodamine phalloidin was used. Cells were fixed and further processed as recommended ([@B2]). The endocytosis test was done according to [@B17]. Calcofluor staining was done on live cells as described ([@B33]).

Latrunculin-A Studies
---------------------

For growth of cells in the presence of Latrunculin-A (LAT-A), a 200-μl logarithmic culture was treated with either LAT-A (Molecular Probes Inc., Eugene, OR) at a concentration of 100 μM in DMSO for 15 min or with DMSO alone (control). The cells were visualized immediately. At the same time point, an aliquot from each culture was fixed and processed for immunofluorescence with rhodamine phalloidin. For cells released from G~0~, a culture enriched in unbudded cells was incubated with LAT-A at 100 μM as described for 4 h ([@B5]) and then visualized using the same conditions as for verprolin-GFP localization studies. Actin cytoskeleton disassembly was verified by staining with rhodamine phalloidin.

The halo assay to assess LAT-A sensitivity was done as described previously ([@B5]). Plates were incubated at 23°C for 48 h. Relative apparent LAT-A sensitivity was calculated according to [@B34].

Results
=======

Additional Actin Causes Allele-specific Suppression of vrp1-1 Phenotypes
------------------------------------------------------------------------

We previously showed that *vrp1-1* cells transformed with a centromere-containing plasmid containing *ACT1*, pT3, or harboring an integrated copy of *ACT1* are able to grow at nonpermissive temperatures ([@B53]). We analyzed actin levels in total cell extracts prepared from wild-type cells (strain T8.1D) or *vrp1-1* cells (strain TZ33) transformed with vector alone or with pT3. When indexed against the cytoplasmic protein Rna1p, actin levels were two to fourfold greater in *vrp1-1* cells bearing pT3 than in either parental (strain T8.1D) or *vrp1-1* (strain TZ33) cells transformed with vector alone (data not shown).

### ACT1 Restores the Cytoskeletal Polarization of vrp1-1 Cells.

Mutant *vrp1-1* cells have a disorganized cytoskeleton. Cortical patches are distributed randomly between mother and bud, no concentration of patches can be detected during any phase of the cell cycle, and no actin cables are visible. The defect is more severe when cells are grown on nonfermentable carbon sources (see mitochondrial defects below), even at permissive temperatures ([@B53]). To determine whether additional actin corrects the defects in actin cytoskeleton organization, cells were grown on lactate medium at the permissive temperature, fixed, and stained with rhodamine phalloidin. Wild-type cells transformed with vector alone have polarized cytoskeletons (Fig. [1](#F1){ref-type="fig"}, *a* and *b*), whereas mutant *vrp1-1* cells bearing the vector alone have shape alterations and a random distribution of cortical patches between mother and bud (Fig. [1](#F1){ref-type="fig"}, *c* and *d*). In contrast, *vrp1-1* cells bearing pT3, encoding *ACT1*, have a wild-type morphology and polarized distribution of cortical patches between the mother and the bud (Fig. [1](#F1){ref-type="fig"}, *e* and *f*). Therefore, a two to fourfold increase in the intracellular concentration of actin confers polarized cytoskeleton and normal shape to *vrp1-1* cells.

### ACT1 Corrects the Endocytosis Defects of vrp1-1 Cells.

Cells with mutations in *VRP1* are defective in endocytosis ([@B32]; [@B54]). It is known ([@B7]; [@B32]) that the actin cytoskeleton plays an essential role in the internalization step of endocytosis in yeast. Many cytoskeletal proteins, such as actin, Sac6p, calmodulin, End3p, End4p, and type I myosins ([@B23]) are necessary for endocytic traffic. To determine whether the defect in endocytosis of *vrp1* mutant cells is related to actin cytoskeleton defects, we studied fluid phase endocytosis ([@B17]) of *vrp1* cells in the presence or absence of the centromere-containing plasmid encoding actin. Parental cells (strain T8.1D) accumulate Lucifer yellow in vacuoles (Fig. [2](#F2){ref-type="fig"}, *A* and *B*), whereas *vrp1-1* mutant cells do not accumulate any detectable levels of this compound (Fig. [2](#F2){ref-type="fig"}, *C* and *D*). However, mutant cells containing pT3 show accumulation of Lucifer yellow in vacuoles in a manner indistinguishable from wild-type cells (Fig. [2](#F2){ref-type="fig"}, *E* and *F*). Therefore, an increase in the intracellular quantity of actin suppresses the endocytosis defect caused by the *vrp1-1* mutation.

### ACT1 Partially Corrects the Mitochondrial Defects of vrp1-1 Cells.

Mutant *vrp1-1* cells have defects in mitochondrial function as assessed by their inability to grow on nonfermentable carbon sources at temperatures exceeding 30°C (Table [II](#TII){ref-type="table"}). In contrast, *vrp1-1* mutant cells grow well at 30°, 34°, and 35°C and poorly at 37° or 38°C on glucose-containing media. *Vrp1-1* mutant cells provided with additional actin grow on glycerol-containing media at temperatures from 30° to 36°C, but not at 38°C (Table [II](#TII){ref-type="table"}). Therefore, a two- to fourfold increase in actin levels partially restores mitochondrial function to *vrp1-1* mutants.

To determine if additional Act1p affects the delivery of proteins to mitochondria, we assessed the functional levels of cytosolic Mod5p-I. Mod5p is a tRNA isopentenyl transferase that modifies tRNAs. Cytosolic levels of Mod5p can be assessed by studying the levels of modified tRNA ^Tyr^ ~UAA~, which in turn are monitored by assaying nonsense suppression of the *lys2-1* allele ([@B53]). Mod5p-I,KR6 is a form of Mod5p-I, with an alteration that provides its quantitative delivery to mitochondria. Parental cells (strain T8.1D) harboring the plasmid-encoding Mod5p-I,KR6 deliver the great majority of Mod5p-I,KR6 to mitochondria. As these cells do not have sufficient cytosolic Mod5p-I,KR6 to modify the tRNA ^Tyr^ ~UAA~ encoded by *SUP11*, they can not grow on media lacking lysine (lys^−^). In contrast, *vrp1-1* cells (strain TZ33) bearing the plasmid encoding Mod5p-I,KR6, grow on lys^−^ media. We analyzed the growth on lys^−^ media of *vrp1-1* mutant cells with and without a centromere-containing plasmid encoding actin. Parental cells (strain T8.1D) bearing YCpLEUMod5p-I,KR6ET and a control centromere-containing plasmid encoding *URA3* alone are able to grow on ura^−^leu^−^ media (Fig. [3](#F3){ref-type="fig"} *a*), but not on ura^−^leu^−^lys^−^ (Fig. [3](#F3){ref-type="fig"} *d*). By contrast, *vrp1-1* cells bearing YCpLEUMod5p-I,KR6ET and the control *URA3* plasmid are able to grow on both ura^−^leu^−^ (Fig [3](#F3){ref-type="fig"} *c*) and ura^−^leu^−^lys^−^ media (Fig. [3](#F3){ref-type="fig"} *f*). Although able to grow well on ura^−^leu^−^ media (Fig. [3](#F3){ref-type="fig"} *b*) *vrp1-1* cells bearing YCp LEUMod5p-I,KR6ET and pT3 containing *ACT1* show an intermediate phenotype on ura^−^leu^−^lys^−^ media (Fig. [3](#F3){ref-type="fig"} *e*). Thus, the partial suppression of the Lys^+^ phenotype in *vrp1-1* cells indicates that excess actin causes a decrease in the functional cytoplasmic pool of Mod5p-I,KR6.

Verprolin Is Required for Bipolar Budding But Not for Axial Budding
-------------------------------------------------------------------

Because verprolin is associated with many actin-related functions and the actin cytoskeleton is required for diploid-specific bipolar budding pattern ([@B51]), we examined whether verprolin affects the budding pattern. Haploid *vrp1::LEU2* cells (Fig. [4](#F4){ref-type="fig"}, *C* and *D*), like their wild-type counterparts (Fig. [4](#F4){ref-type="fig"}, *A* and *B*), bud axially. In contrast, diploid cells homozygous for *vrp1::LEU2* (Fig. [4](#F4){ref-type="fig"}, *G* and *H*) are unable to bud bipolarly like wild-type cells do (Fig. [4](#F4){ref-type="fig"}, *E* and *F*); instead, they bud randomly. Introduction of the *VRP1--GFP* fusion on a low copy plasmid which complements the ts growth of the mutant cells leads to restoration of the bipolar budding pattern (Fig. [4](#F4){ref-type="fig"}, *I* and *J*). Thus, verprolin is required for bipolar budding pattern in diploid cells, but does not appear to influence the axial budding pattern of haploid cells. Although the budding pattern in diploid cells homozygous for *vrp1::LEU2* is random, the cells are still able to form buds, indicating that verprolin is required for bud site-selection and not bud growth per se.

Verprolin Interacts with Actin in the Two-Hybrid System
-------------------------------------------------------

*ACT1* and *VRP1* show allele-specific interactions as *ACT1* can suppress the *vrp1-1* mutation, but not the *vrp1::LEU2* disruption. Single-copy suppression and allele-specific interactions provide genetic evidence that Act1p and Vrp1p may physically interact. We tested the genetic predictions by using the two-hybrid system ([@B20]) to detect verprolin--actin physical interactions. Also, because verprolin has 12 stretches of three to nine polyprolines and polyproline stretches have been shown to bind another actin-binding protein, profilin, we tested whether there is an interaction between verprolin and profilin. Each gene was cloned into the vector encoding the Gal4p DNA-binding domain and the vector encoding the DNA-activating domain and all possible combinations were analyzed. Neither *VRP1* nor *ACT1* activated the reporter genes, *LacZ* and *HIS3*, when transformed alone in the Y190 tester strain. pDBD-PFY, encoding profilin appended to the Gal4p DNA-binding domain, activated the reporter genes by itself. However, pDAD-PFY, encoding profilin appended to the Gal4p transcription activation domain did not. Therefore, pDAD-PFY was used to test interactions between pDBD-ACT1 and pDBD-VRP1. We found that verprolin interacts with actin but not with profilin (Table [III](#TIII){ref-type="table"}). Both *LacZ* and *HIS3* transcription (at 100 mM 3-amino- 1,2,4-triazole) are activated when *VRP1* and *ACT1* are both present. However, the pDAD-VRP1 plasmid is mitotically unstable; the loss of plasmid correlates with the loss of blue color in these cells. The tendency to lose this plasmid may be related to our observations that overexpression of verprolin is detrimental to cells (data not shown). As expected ([@B3]), we detected interactions between actin--profilin and actin--actin (Table [III](#TIII){ref-type="table"}). We found no evidence for the dimerization of verprolin, since the pair pDAD-VRP1 and pDBD-VRP1 did not activate either reporter gene.

An Actin-binding Domain Maps at Amino Terminus of Verprolin
-----------------------------------------------------------

A computer search using the BEAUTY program ([@B50]) revealed that the amino terminal 70 amino acids of verprolin show strong homology with similarly located regions in a number of proteins from various species: *Caenorhabditus elegans* CELR144.4 gene product (GenBank/EMBL/DDBJ accession number [U23515](U23515)), *Xenopus laevis* proline rich protein (GenBank/EMBL/DDBJ accession number [X68249](X68249)) and rat SH3 domain-binding protein (GenBank/EMBL/DDBJ accession number [U25281](U25281)) (Fig. [5](#F5){ref-type="fig"} *A*). All these genes code for proteins of unknown function. Further, inspection of the core of this extended motif revealed the presence of a hexapeptide, LKKAET, conserved in a variety of actin-binding proteins, including thymosin, actobindin, tropomyosin, villin, dematin, myosin heavy chain, fimbrin, α-actinin, and plastin (Fig. [5](#F5){ref-type="fig"} *B*).

To determine whether there is an actin-binding domain at the amino terminus of verprolin (Fig. [5](#F5){ref-type="fig"} *C*), *VRP1* deletion and out-of-frame constructs were generated (Fig. [6](#F6){ref-type="fig"}). If the actin--verprolin interactions detected by the two- hybrid method result from the interaction of the region of verprolin containing the LKKAET motif, plasmids encoding this region of verprolin should then generate proteins that interact with actin. Deletion of the carboxy-terminal 455 amino acids generated pDAD-VRP1ΔSal coding for verprolin amino acids 1--362. This part of verprolin interacts with actin in the two-hybrid system (Fig. [6](#F6){ref-type="fig"}). pDAD-VRP1ΔSalΔKpn1-3, which fuses in-frame the first 70 with the last 100 codons of verprolin, generates a shorter version of verprolin that shows strong interaction with actin. Finally, pDAD-VRP1ΔSalΔKpn1-2 that has an out-of-frame fusion coding for only the first 70 amino acids of verprolin was found to code for a protein able to bind actin. Therefore, the first 70 amino acids of verprolin are sufficient for actin-verprolin interactions in the two-hybrid system.

To test whether the LKKAET motif that resides within the 70--amino acid domain is necessary for the verprolin-- actin interaction, we generated a mutant version of the sequence encoding this hexamer. Based on the alignment in Fig. [5](#F5){ref-type="fig"} *B* and on mutagenesis studies of β-thymosin ([@B46]), we chose to mutate the two basic residues of this sequence to acidic residues. We found that the 70--amino acid motif encoding the sequence LEEAET was unable to interact with actin in the two-hybrid system. Therefore, as anticipated, the hexamer is necessary for the interaction of verprolin with actin.

If verprolin--actin interactions are solely dependent upon the 70--amino acid motif, constructs not containing this motif should then generate proteins that fail to interact with actin. To test this, a fusion between the Gal4p DNA-activating domain and a fragment of *VRP1* encoding amino acids 71--817 (pDAD-VRP1 71--817) was constructed. pDAD-VRP1 71--817 shows less activation of LacZ or *HIS3* reporter genes than pDAD-VRP1ΔSalΔKpn1-2. Therefore, whereas the first 70 amino acids of verprolin, containing the LKKAET motif, are sufficient for binding to actin, other actin-binding sequences might reside in verprolin and/or other sequences may influence the efficiency of actin-binding.

Suppression of *vrp1-1* phenotypes by actin indicate that verprolin--actin interactions are important for the function of verprolin. If so, versions of verprolin lacking the actin-binding domain should fail to complement *vrp1* mutations. Fortuitously, the plasmid encoding the entire verprolin appended to the Gal4p DNA-binding domain (pDAD-VRP1) constructed for the two-hybrid analyses generates sufficient hybrid protein to complement *vrp1-1* (Fig. [6](#F6){ref-type="fig"}), even though most of the protein locates to the nucleus as assessed by indirect immunofluorescence (not shown). None of the other deletion constructs was able to complement *vrp1-1.* In particular, pDAD-VRP1 71--817, lacking the 70--amino acid actin-binding domain failed to code for a functional verprolin (Fig. [6](#F6){ref-type="fig"}). Provided that this shortened version of verprolin maintains its native conformation, we can conclude that the actin-binding domain of verprolin is important for its in vivo function.

Cellular Location of Verprolin
------------------------------

The allele-specific interactions described above and the results from the two-hybrid system provide evidence that verprolin and actin interact directly. To test the prediction that verprolin localizes with the actin cytoskeleton, we assessed the natural distribution of verprolin tagged with GFP ([@B9]) in live cells. Wild-type cells (strain T8.1D) as well as mutant *vrp1-1* (strain TZ33) and *vrp1:: LEU2* haploid (strain T65.1D) or diploid (strain GVY1) cells were transformed with low copy YCpVRP1GFP plasmid encoding verprolin--GFP. *VRP1--GFP* complements both the *vrp1-1* mutation and the *vrp1::LEU2* disruption. Verprolin--GFP expressed from YCpVRP1GFP plasmid has a similar distribution in wild-type, *vrp1-1*, *vrp1::LEU2*, and *vrp1::LEU2*/*vrp1::LEU2* mutant cells. However, the signal is most easily visualized in *vrp1::LEU2* (Fig. [7](#F7){ref-type="fig"}) and *vrp1::LEU2*/*vrp1::LEU2* cells bearing YCpVRP1GFP plasmid. In cells preparing to bud, verprolin is localized at the presumptive budding site (Fig. [7](#F7){ref-type="fig"}, *a* and *b*). As the bud starts to grow, verprolin concentrates at the tip of the bud (Fig. [7](#F7){ref-type="fig"}, *c* and *d*). There is very little if any verprolin in the cytoplasm. In older buds verprolin has punctate staining, much like cortical patches (Fig. [7](#F7){ref-type="fig"}, *e* and *f*). Sometimes patches are at the tip of the buds and sometimes they are eccentric. When the cells prepare for cytokinesis, there are two rings of verprolin around the mother-bud neck (Fig. [7](#F7){ref-type="fig"}, *g* and *h*). Similar actin-containing rings are characteristic for this part of the yeast life cycle ([@B1]) and at least one other actin-binding protein, Aip3p, locates at these rings during this part of the cell cycle ([@B4]). In freshly divided cells, verprolin patches appear randomly distributed. The punctuate staining of verprolin-GFP is remarkably similar to that of actin-GFP ([@B14]).

To determine whether verprolin and actin cortical patches co-localize, we used indirect immunofluorescence to locate a HA-tagged version of Vrp1p encoded by the low copy vector YCpVRP1-HA. This verprolin--HA fusion fully complements, in either single or multicopy, the *vrp1-1* and the *vrp1::LEU2* mutations in haploid or diploid cells. Actin was detected using fluorescent phalloidin. As it was not possible to stain the cytoskeleton with phalloidin on slides, the procedure was modified to perform all reactions in solution (see Materials and Methods). As was found in studies of live cells, verprolin in fixed cells is located in a cell cycle--dependent fashion to positions also occupied by the actin cortical cytoskeleton (Fig. [8](#F8){ref-type="fig"}). The verprolin patches overlap most often with actin patches stained with phalloidin. Interestingly, patches in mother cells not associated with the presumptive bud appear to locate at points of actin cable branch sites (Fig. [8](#F8){ref-type="fig"}). We conclude that verprolin is present during the whole cell cycle and is located at or very near the actin cortical patches.

Verprolin Localization is Actin Independent
-------------------------------------------

Verprolin exhibits a cell cycle--dependent pattern of localization which closely resembles that of its interactor, actin. To explore the co-dependence of the subcellular distribution of Act1p and Vrp1p we used a pharmacological tool which recently has been shown to allow the temporal dissection of events involved in bud morphogenesis. LAT-A, a macrolide isolated from a marine sponge, is a potent inhibitor of actin cytoskeleton assembly in vertebrates ([@B41]) and yeast ([@B5]). We examined the consequences that disruption of actin cytoskeleton with LAT-A have on verprolin-GFP localization. Cultures of *vrp1::LEU2*/*vrp1::LEU2* diploid cells (strain GVY1) containing the *VRP1--GFP* fusion on a low copy vector were grown for 15 minutes in the presence of 100 μM LAT-A or in the presence of DMSO diluent alone and visualized immediately by microscopy. At the same time point, an aliquot was withdrawn from each culture, fixed, and processed for rhodamine phalloidin staining. Whereas the actin cytoskeleton of LAT-A treated cells is virtually absent (compare Fig. [9](#F9){ref-type="fig"}, *G* and *H* to Fig. [9](#F9){ref-type="fig"}, *C* and *D*), the localization of verprolin--GFP is unaffected (compare Fig. [9](#F9){ref-type="fig"}, *E* and *F*, to Fig. [9](#F9){ref-type="fig"}, *A* and *B*). Thus, maintenance of the intracellular polarized location of verprolin is not dependent upon the integrity of actin cytoskeleton.

To determine whether verprolin requires the actin cytoskeleton to achieve its location, cultures enriched in unbudded cells ([@B5]) were grown for 4 h in 100 μM LAT-A and then visualized by microscopy. Under these conditions, while the actin cytoskeleton is disassembled (data not shown), the majority of the cells have verprolin-GFP at the presumptive budding site (Fig. [9](#F9){ref-type="fig"}, *I* and *J*). This indicates that verprolin achieves its location inside the cell through an actin-independent pathway.

Effect of Verprolin on Actin Cytoskeleton Stability
---------------------------------------------------

Sensitivity to LAT-A varies among actin cytoskeleton-associated mutants and can be used as an indicator of the effect the respective proteins have on the stability of the actin cytoskeleton ([@B5]). To test the sensitivity of *vrp1* mutant strains to LAT-A we used a halo assay. The *vrp1::LEU2* strain harboring the *VRP1* gene on a centromeric plasmid is more resistant to LAT-A than is the same strain containing vector alone (Fig. [10](#F10){ref-type="fig"}, compare *A* and *B*). Therefore, disruption of *VRP1* gene confers sensitivity to LAT-A. The relative apparent sensitivity ([@B34]) for *vrp1::LEU2* compared to *vrp1::LEU2* bearing YCpVRP1 is 2.5, a value comparable to that of other cytoskeletal proteins ([@B5]). This result suggests that verprolin acts to increase actin cytoskeleton stability. Also, we compared the sensitivity of *vrp1-1* cells bearing pT3 to that of *vrp1-1* cells bearing YCpVRP1 or an empty vector as control. Although no difference is apparent between *vrp1-1* cells bearing *VRP1* or the empty vector at the permissive temperature, *vrp1-1* cells bearing *ACT1* on pT3 show resistance to LAT-A even at a concentration of 2 mM (Fig. [10](#F10){ref-type="fig"} *E*).

Discussion
==========

Verprolin Is an Actin-binding Protein Important for Numerous Actin-associated Processes
---------------------------------------------------------------------------------------

Verprolin was identified as a protein important for both sorting of Mod5p-I between mitochondria and cytosol ([@B53]) and endocytosis ([@B32]). *vrp1-1* mutant cells have an aberrant actin cytoskeleton which is most apparent at permissive temperatures if the cells are grown on nonfermentable carbon sources ([@B53]). Allele-specific suppression of *vrp1-1* by a single additional copy of *ACT1* ([@B53]) indicated that verprolin and actin physically interact. To confirm the genetic predictions and to understand the nature of these interactions, we examined *vrp1-1* phenotypes, in addition to temperature sensitive growth, for suppression by *ACT1.* We found that *ACT1* suppresses *vrp1-1* defects in cytoskeletal polarization, endocytosis, and mitochondrial function. Therefore, it is likely that all phenotypes of *vrp1* mutants relate to an abnormal cytoskeleton.

Our studies of fluid phase endocytosis are consistent with other observations that some, but not all, cytoskeletal mutations show defects in endocytosis ([@B32]; [@B49]; [@B54];). Our data support the involvement of the actin cytoskeleton and, more probably, cortical actin patches as components of the endocytic machinery. Restoration of endocytosis in *vrp1-1* mutant cells by additional actin indicates that their endocytosis defect is most likely a direct consequence of a defective cytoskeleton.

Actin supplied from a centromere-containing plasmid also partially corrects the *vrp1-1* mitochondrial deficiency as assessed by growth on nonfermentable carbon sources, and restores near parental cytoplasmic levels of Mod5p-I,KR6 as assessed by nonsense suppression studies. The involvement of the actin cytoskeleton with delivery of proteins to mitochondria and with mitochondrial function implicates a novel function for the actin cytoskeleton. Ideas as to how mitochondria and the cytoskeleton might interrelate are outlined below.

Because the actin cytoskeleton has been shown to be important for bud-site selection ([@B10]; [@B51]), we examined the budding pattern of diploid *vrp1::LEU2*/*vrp1::LEU2* and haploid *vrp1::LEU2* cells. Verprolin is required for the bipolar budding pattern, but not for the axial budding pattern. The randomization of budding pattern in *vrp1::LEU2*/*vrp1::LEU2* diploids indicates that verprolin is among the proteins required for bipolar site selection in these cells.

We used the two-hybrid system to test the genetic prediction that actin and verprolin interact. We found that actin and verprolin are able to bind each other. The data indicate that verprolin is a new member of the family of actin-binding proteins. The first 70 amino acids of verprolin are homologous with a similar region of a group of proteins of unknown function from three higher eukaryotes. Using the two-hybrid system and deletion analysis we show that the 70 amino acid conserved domain in verprolin is sufficient for interaction with actin.

The hexapeptide motif LKKAET, found in a variety of actin-binding proteins, is in the middle of this conserved domain. The conservation of the 70--amino acid domain and the possession of a motif similar to the LKKAET hexapeptide within this domain leads us to predict that these *C. elegans*, *Xenopus*, and rat proteins of unknown function will subsequently be shown to interact with actin. The hexapeptide motif has been shown to directly bind actin. Actobindin, a small actin-binding protein from *Acanthamoeba*, contains two LKHAET hexapeptides, between amino acids 15 to 20 and 51 to 56. Lys^16^ and Lys^52^ of actobindin can be cross-linked to particular amino acids of actin ([@B45]; [@B44]). The LKKEKG hexapeptide is crucial for the morphogenic activity of the actin-bundling protein villin. In vitro studies with a 22--amino acid synthetic peptide including the villin LKKEKG hexapeptide showed that it is part of an F-actin binding site involved in the conversion of G-actin to a polymerization-competent form. The Ser^809^-Lys^825^ fragment of villin, containing the first five amino acids of the LKKEKG hexapeptide, is important for binding to preformed actin filaments, but insufficient for their induction ([@B21]). Moreover, conversion of KKEK to KEEE in villin significantly decreases villin\'s morphogenic activity. Finally, the LKKTET hexapeptide in thymosin is essential for binding to actin; mutation of Lys^18-19^ to Glu drastically abolishes cross-linking with monomeric actin ([@B46]). By two-hybrid analysis we showed that the analogous alteration of the verprolin LKKAET motif to LEEAET destroys the ability of the 70--amino acid domain to interact with actin. Thus it appears that the function of this motif is conserved from lower to higher eukaryotes.

A similarity also exists between the 70--amino acid homology domain of verprolin and COOH-terminal regions of N-WASP and WASP, both of which contain less conserved versions of the LKKAET motif ([@B31]; [@B43]). Both WASP and N-WASP influence the organization of the actin cytoskeleton. WASP colocalizes with actin. N-WASP contains a tripartite actin-binding motif of two shorter verprolin-like domains, one of which terminates right in the middle of the LKKAET motif followed by a cofilin-like actin-binding motif. When only the verprolin-like part was tested for actin binding in vitro, there was very poor binding of N-WASP to actin. When the whole motif (including the cofilin-like part) was included, actin binding occured ([@B31]). The data suggest that part of the 70--amino acid region of verprolin, in addition to LKKAET, participates in actin binding.

Verprolin Localization Is Independent of Actin Cytoskeleton
-----------------------------------------------------------

The changes in the cellular distribution of verprolin-GFP during the cell cycle are very similar to the pattern of changes that the actin cortical patches undergo during the cell cycle. However, whereas the actin cytoskeleton is disassembled using the actin assembly inhibitor LAT-A, verprolin\'s localization is unaffected. Therefore, verprolin does not require actin to achieve or maintain its polarized cellular localization. This is not a unique case. Other proteins involved in cell polarity development, including Myo2p, calmodulin, and Bud6/Aip3p ([@B5]), achieve polarized localization by an actin-independent pathway. Also, polarity establishment proteins Cdc42p and Bem1p become polarized even though the actin cytoskeleton is totally disassembled ([@B5]). Thus, it appears that yeast cells have evolved an actin-independent pathway for localizing polarity development proteins. By contrast, other actin-binding proteins including Arp2p, proteins involved in secretion such as Sec4p, Sec8p, and the kinesin-like protein Smy1p require actin to achieve their polarized localization ([@B5]).

The ability of verprolin to localize independently from actin as well as its role in bud-site selection indicate that it functions in cell polarity development and maintenance. As supported by data regarding verprolin\'s actin-binding properties, its spatial co-localization with actin and its downstream effects on cytoskeleton morphogenesis and stability, verprolin might convey the polarity development information to the actin cytoskeleton via acting as an anchor for the actin cytoskeleton.

Possible Roles of Verprolin in Mitochondrial Function and Mitochondrial Protein Sorting
---------------------------------------------------------------------------------------

How would verprolin affect cytoskeletal morphology and, at the same time, be involved in mitochondrial function and Mod5p-I mitochondria/cytosol sorting? A priori, three mechanisms could account for the mitochondrial phenotypes: defective mitochondrial movement, altered protein delivery, and disruption of mRNA sorting. Although it is known that movement of mitochondria is impaired by *ACT1* mutations that perturb the myosin-binding site ([@B40]) and it is known that many, but not all, thermal sensitive *act1* alleles cause abnormal mitochondrial distribution and morphology ([@B15]), we do not favor the model that altered mitochondrial distribution/morphology accounts for the mitochondrial defects observed in *vrp1* mutant cells. This is because even on lactate-containing media when the cytoskeleton is clearly depolarized, *vrp1* mutants show no obvious defects in mitochondrial distribution or morphology ([@B53] and these studies). Recently, it has been shown that Mft52p, which affects the delivery of particular fusion proteins to yeast mitochondria, is a component of a greater than 5,000-kD cytosolic particle. Mft52p interacts with mitochondrial targeting sequences and it has been proposed that Mft52p plays a role in co-translational delivery of proteins to mitochondria ([@B8]; for review see [@B29]). If such a co-translational mechanism required a role of the actin cytoskeleton, then the mitochondrial defects we detect in *vrp1* mutant cells could be accounted for by defects in this putative co-translational mechanism of mitochondrial import.

Alternatively, the actin cytoskeleton could be involved in the delivery of mRNAs encoding mitochondrial proteins to the vicinity of mitochondria. In higher eukaryotes, the actin cytoskeleton has a role in mRNA sorting (Singer et al., 1992; [@B6]). mRNA sorting plays an important role in the cellular distribution of cytoskeletal proteins ([@B28]; [@B26]) and numerous morphogens like Vg-1 ([@B52]), *nanos* ([@B22]) and *oskar* ([@B25]). The cellular distribution of actin itself has been shown to occur via sorting of actin mRNA to appropriate subcellular locations ([@B42]). Moreover, there are reports implicating mRNA sorting in the delivery of proteins to mitochondria in higher eukaryotes ([@B36]; [@B35]; for review see [@B29]).

Little is known about sorting of mRNA in yeast. *ASH1* mRNA is one example of a mRNA which is selectively transported to and expressed solely in daughter cells ([@B30]). The actin cytoskeleton is actively involved in the localized transport of *ASH1* transcript since mutations of cytoskeletal genes like *ACT1*, *PFY1*, *TPM1*, and *BNI1* impair the transport of *ASH1* mRNA to daughter cells ([@B30]). If mRNAs encoding mitochondrial proteins are also sorted in yeast, as they are in higher eukaryotic cells, then lesions similar to those affecting the ability of yeast to distribute *ASH1* mRNA might also affect the distribution of transcripts encoding mitochondrial proteins. The actin-binding protein Bni1p, required for correct sorting of *ASH1* mRNA to daughter cells ([@B30]), binds the polarity establishment protein Cdc42p and also Bud6/Aip3p ([@B19]), another actin-binding protein whose intracellular location ([@B4]) is remarkably similar to that of verprolin. Like verprolin, Bud6/Aip3p is required for bipolar, but not for axial budding pattern ([@B4]), and both verprolin and Bud6/Aip3p ([@B5]) can achieve their polarized location even though the actin cytoskeleton is disassembled. Of these three proteins, only Bni1p has been tested and shown to be responsible for sorting of *ASH1* mRNA. The prediction is that verprolin will be found to play a role in mRNA sorting.
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S. cerevisiae Strains Used in This Study

  Strain      Genotype                                                                                                                     Reference
  -------- -- ------------------------------------------------------------------------------------------------------------------------- -- ---------------------------------------------------------------
  T8.1D       *MATα SUP11 ade2-1 mod5-1 ura3-1 lys2-1 leu2-3,112 his4-519*                                                                 [@B53]
                                                                                                                                           
  TZ33        *MATα SUP11 ade2-1 mod5-1 ura3-1 lys2-1 leu2-3,112 his4-519 vrp1-1*                                                          [@B53]
                                                                                                                                           
  T65.1D      *MATα leu2-3, 112 ade1 ura3-52 Ile^−^ MEL1 vrp1::LEU2*                                                                       [@B53]
                                                                                                                                           
  Y190        *MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3,112 URA3::GAL*- -\> *lacZ  LYS2::GAL(UAS)*- -\>*HIS3 cyh^r^*          S.J. Elledge, gift (Baylor College  of Medicine, Houston, TX)
  Sc467       *MATα/MAT* **a** *leu2-3,112/leu2-3,112 ade1/ade1 ura3-52/ura3-52 Ile* ^−^/*Ile* ^−^ *MEL1/MEL1*                             [@B53]
                                                                                                                                           
  GVY1        *MATα/MAT* **a** *leu2-3,112/leu2-3,112 ade1/ade1 ura3-52/ura3-52 Ile* ^−^/*Ile* ^−^ *MEL1/MEL1  vrp1::LEU2/vrp1::LEU2*      This laboratory

![Cytoskeletal polarization is restored in *vrp1-1* cells (strain TZ33) by two- to fourfold increases in the level of actin. Representative cells of wild-type strain T8.1D bearing an empty plasmid in *a* and *b*; *vrp1-1* mutant cells (strain TZ33) bearing an empty plasmid in *c* and *d*; and *vrp1-1* cells plus *ACT1* on the centromere-containing plasmid pT3 in *e* and *f.* Cells were grown on 2% lactate medium at permissive temperature, fixed as described ([@B2]) and then stained with rhodamine-phalloidin for 1 h. Bar, 3 μm.](JCB14557.f1){#F1}

![Fluid-phase endocytosis is restored in *vrp1-1* cells (strain TZ33) by additional actin. Lucifer yellow uptake in wild-type (strain T8.1D) cells transformed with vector alone in *A* and *B*; *vrp1-1* mutant cells bearing vector alone (*C* and *D*); and *vrp1-1* cells bearing *ACT1* on pT3 plasmid (*E* and *F*). Cells were grown at permissive temperature and then incubated with Lucifer yellow for 2 h. (*A*, *C*, and *E*), FITC channel. In *B*, *D*, and *F*, the same cells visualized under DIC. Bar, 3 μm.](JCB14557.f2){#F2}

###### 

Growth Characteristics of vrp1-1 Cells Bearing ACT1 on the Centromere-containing Plasmid pT3

                        Glycerol      Glucose                                              
  ------------------ -- ---------- -- --------- -- ---- -- ---- -- ---- -- ---- -- ---- -- ----
  *VRP1*                \+            \+           \+      \+      \+      \+      \+      \+
  *vrp1-1*              \+            ±            −       −       \+      \+      \+      −
  *vrp1-1* and pT3      \+            \+           \+      −       \+      \+      \+      \+

Growth was assessed after incubating the plates for two days at the indicated temperature. Absence of growth is indicated by (−); wild-type growth indicated by (+), (±) designates poor growth.  

![Extra actin partially suppresses the Lys^+^ phenotype of *vrp1-1* cells. The plate in the left is ura^−^leu^−^ and the one in the right is ura^−^leu^−^lys^−^. Parental T8.1D cells (*a* and *d); vrp1-1* cells (strain TZ33), (*c* and *f*); *vrp1-1* cells bearing pT3 (encoding actin) (*b* and *e*). All strains have Mod5-I,KR6ET gene on a centromere-containing plasmid; the ura^−^leu^−^ master plate was first replica plated to ura^−^leu^−^lys^−^ plate and then to ura^−^leu^−^ plate. For all strains, growth was assessed at 23°C.](JCB14557.f3){#F3}

![Budding pattern phenotypes of haploid and diploid *vrp1::LEU2* mutant strains and rescue of mutant phenotype by *VRP1-GFP.* Logarithmic cultures of each strain were grown in selective media at 23°C and then stained with Calcofluor to visualize bud scars. (*A*) *vrp1::LEU2* (strain T65.1D) cells bearing YCpVRP1GFP plasmid show normal axial budding pattern; (*C*) *vrp1::LEU2* (strain T65.1D) cells bearing vector alone show axial pattern; (*E*) wild-type diploid strain Sc467 bearing an empty plasmid shows bipolar budding pattern; (*G*) diploid *vrp1::LEU2*/*vrp1:: LEU2* cells bearing vector alone show random budding pattern; (*H*) morphologically, a large proportion of these cells have multiple buds and shape defects; (*I*) restoration of bipolar budding in homozygous diploid *vrp1::LEU2*/*vrp1::LEU2* cells by the *VRP1-GFP* gene on a centromere-containing plasmid. These cells have normal morphology (*J*). *B*, *D*, *F*, *H*, *J* are DIC images of *A*, *C*, *E*, *G*, *I*, respectively. Bar, 2.5 μm.](JCB14557.f4){#F4}

###### 

Two-Hybrid Interactions between Verprolin, Actin, and Profilin

                                                      pDBD      pDBD-ACT1      pDBD-PFY      pDBD-VRP1
  ------------------------------------------------ -- ------ -- ----------- -- ---------- -- -----------
  pDAD                                                −         −              \+            −
  pDAD-ACT1                                           −         \+             \+            \+
  pDAD-PFY                                            −         \+             \+            −
  pDAD-VRP1[\*](#TFIII-150){ref-type="table-fn"}      −         ±              \+            −

 The pDAD-VRP1 plasmid is mitoticallly unstable.  

###### 

The actin-binding domain of verprolin. (*A*) Homologies between the first 70 amino acids of verprolin and *C. elegans* CELR 144.4 protein ("CELR144.4", GenBank/EMBL/DDBJ accession number [U23515](U23515)), *X. laevis* proline-rich protein ("Xlpro-rich", GenBank/EMBL/DDBJ accession number [X68249](X68249)), and rat SH3-domain--binding protein ("RNU25281", GenBank/EMBL/DDBJ accession number [U25281](U25281)). Alignment was done using BOXSHADE 3.21 program running on a WWW server at ISREC, Switzerland. Asterisks designate the position of the LKKAET hexapeptide. (*B*) LKKAET-like motifs in various cytoskeletal proteins. (*C*) Diagram of the localization of the actin-binding domain in verprolin. The LKKAET motif is in bold and underlined. The 11 black bars correspond to potential SH3-binding domains having the general pattern APPL/IP.

![](JCB14557.f5a)

![](JCB14557.f5b)

![](JCB14557.f5c)

![Mapping of the actin-binding domain of verprolin using two-hybrid analysis. Various DNA fragments encoding truncated Vrp1p were cloned in-frame with the Gal4 DNA-activation domain in vector pDAD and the resultant plasmids were transformed into Y190 strain bearing the pDBD--ACT1 construct encoding actin. Association of verprolin with actin was examined by the qualitative assay for β-galactosidase and by assessing growth on media-lacking histidine in the presence of 100 mM 3-amino-1,2,4-triazole. Numbers represent the length in amino acids. Asterisks designate mitotic instability of pDAD-VRP1 and pDAD-VRP1ΔSal plasmids. (*N.D.*) not done.](JCB14557.f6){#F6}

![In vivo localization of verprolin-GFP fusion in *vrp1::LEU2* disruptant (as shown by arrowheads). (*a* and *c*) A verprolin cap marks the site where the potential bud will form. (*e*) Verprolin localizes to the bud in patches-like structures. (*g*) Cells preparing for cytokinesis have two rings of verprolin-GFP around the neck. *b*, *d*, *f*, and *h* are DIC images of *a*, *c*, *e*, and *g* frames, respectively. Bar, 2 μm.](JCB14557.f7){#F7}

![Co-localization of verprolin-HA and actin. GVY1 cells bearing hemagglutinin-tagged *VRP1* on a centromere-containing vector (YCpVRP1-HA) were fixed and stained with 12CA5 antibody against the hemagglutinin tag and then co-stained with Oregon green phalloidin as described in Methods. In *A--D* representative cells bearing the verprolin-HA fusion are shown. The same cells, visualized in the FITC channel to detect F-actin, are shown in *E*, *F*, *G*, and *H.* The two proteins co-localize in many of the cortical patches. However, apparently there are actin patches which do not seem to contain verprolin and vice versa. Bar, 1.5 μm.](JCB14557.f8){#F8}

![Localization of verprolin-GFP in the absence or presence of LAT-A in diploid *vrp1::LEU2*/*vrp1::LEU2* cells (strain *GVY1*) containing YCpVRP1GFP plasmid. (*A--H)* Cells were grown to logarithmic phase, the culture was then divided in two: half was treated with DMSO alone for 15 min *(A--D*) and half with LAT-A solubilized in DMSO for 15 min (*E--H*). (*I* and *J*), a separate culture of cells enriched for unbudded cells was treated for 4 h with LAT-A solubilized in DMSO. (*A*) Localization of verprolin-GFP in the absence of LAT-A shows the polarized localization of verprolin at the presumptive budding site, in small buds, and at the mother-bud neck; (*C*) An aliquot of the culture used in (*A*) was fixed and further stained with rhodamine phalloidin to confirm the normal morphology of actin cytoskeletons; (*E*) Localization of verprolin-GFP in a logarithmic culture after incubation with LAT-A for 15 min. Verprolin-GFP maintains its intracellular localization at the mother-bud neck or at the tip of buds. (*G*) An aliquot of the culture used in *E* was fixed and stained with rhodamine phalloidin. Actin cytoskeletons of these cells are disassembled. (*I*) Localization of verprolin-GFP in the presence of LAT-A (4 h) in cells exiting G~0~. The verprolin-GFP signal is present at the presumptive budding site while the actin cytoskeletons of these cells are virtually absent (not shown). *B*, *D*, *F*, *H*, and *J* are DIC images of *A*, *C*, *E*, *G*, and *I*, respectively. Bar, 2 μm.](JCB14557.f9){#F9}

![Halo assay testing the sensitivity of *vrp1* mutant strains to LAT-A. (*A*) *vrp1::LEU2* cells (strain T65.1D) bearing the *VRP1* gene on the centromeric plasmid YCpVRP1. (*B*) *vrp1:: LEU2* cells bearing a vector alone. (*C*) *vrp1-1* cells (strain TZ33) bearing *VRP1* gene on the centromeric plasmid YCpVRP1. (*D*) *vrp1-1* cells (strain TZ33) with vector alone. (*E*) *vrp1-1* cells (strain TZ33) bearing *ACT1* gene on plasmid pT3. Concentrations of LAT-A are: 0 (*top*), 0.5 mM (*right*), 1 mM (*bottom*), and 2mM (*left*). Strains were grown on ura^−^ selective media at 23°C for 48 h.](JCB14557.f10){#F10}
